AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8741162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1727996 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive prenatal care
Number of subjects: 428
Study 1727996 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 428
Study 2987139 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (50 g) given 5 min after dextropropoxyphene hydrochloride (130 mg)
Number of subjects: 6
Study 2987139 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (50 g) followed by 12.5 g at 6 h intervals
Number of subjects: 6
Study 2987139 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidification of urine
Number of subjects: 6
Study 2987139 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinization of urine
Number of subjects: 6
Study 2987139 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary pH influence
Number of subjects: 6
Study 31044492 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg daily
Number of subjects: 84
Study 31044492 — intervention group
Group type: COMPARATOR
Intervention: Oral tetracycline 250 mg bd and topical benzoyl peroxide 2.5%
Number of subjects: 84
Study 29135357 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride (PH)
Number of subjects: 71
Study 29135357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 71
Study 24480761 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocating saw
Number of subjects: 20
Study 24480761 — intervention group
Group type: COMPARATOR
Intervention: Piezosurgery device
Number of subjects: 20
Study 22957501 — intervention group
Group type: COMPARATOR
Intervention: Standard best practice care (SBP)
Number of subjects: 44
Study 22957501 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard best practice care (SBP+RM)
Number of subjects: 44
Study 20456303 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily
Number of subjects: 125
Study 20456303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 17346763 — intervention group
Group type: EXPERIMENTAL
Intervention: Rods (0.002‐0.2 Trolands)
Number of subjects: 0
Study 17346763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cones (200 Trolands)
Number of subjects: 0
Study 17346763 — intervention group
Group type: EXPERIMENTAL
Intervention: Rods and Cones (2‐20 Trolands)
Number of subjects: 0
Study 15626549 — intervention group
Group type: EXPERIMENTAL
Intervention: Public Health Dose (17.5 kcal/kg/week, 3 or 5 days/week)
Number of subjects: 80
Study 15626549 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose (7.0 kcal/kg/week, 3 or 5 days/week)
Number of subjects: 80
Study 15626549 — intervention group
Group type: COMPARATOR
Intervention: Control (3 days/week flexibility exercise)
Number of subjects: 80
Study 12081121 — intervention group
Group type: EXPERIMENTAL
Intervention: L1 group (lower limbs in neutral position when analgesic level reached L1 dermatome)
Number of subjects: 90
Study 12081121 — intervention group
Group type: COMPARATOR
Intervention: T6 group (lower limbs in neutral position when analgesic level reached T6 dermatome)
Number of subjects: 90
Study 10208996 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame count (CTFC) measured at 90 minutes after thrombolytic administration.
Number of subjects: 1248
Study 10208996 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame count (CTFC) as an independent predictor of in-hospital mortality.
Number of subjects: 1248
Study 10208996 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame count (CTFC) in patients with TIMI grade 3 flow.
Number of subjects: 1248
Study 10208996 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame count (CTFC) in patients with TIMI grade 3 flow (CTFC ≤40).
Number of subjects: 1248
Study 8004854 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to nursing, social work, physiotherapy, occupational therapy, or dietary services for potential discharge planning in Hospital A
Number of subjects: 421
Study 8004854 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to nursing, social work, physiotherapy, occupational therapy, or dietary services for potential discharge planning in Hospital B
Number of subjects: 421
Study 8004854 — intervention group
Group type: COMPARATOR
Intervention: Control group in Hospital A
Number of subjects: 421
Study 8004854 — intervention group
Group type: COMPARATOR
Intervention: Control group in Hospital B
Number of subjects: 421
Study 2599668 — intervention group
Group type: EXPERIMENTAL
Intervention: Keto-analogues (200 mg/kg/d) with low-protein diet (0.4 g/kg/d)
Number of subjects: 15
Study 2599668 — intervention group
Group type: EXPERIMENTAL
Intervention: Keto-analogues (200 mg/kg/d) with normal protein diet (1 g/kg/d)
Number of subjects: 15
Study 30920411 — intervention group
Group type: EXPERIMENTAL
Intervention: At least twice daily screening led by respiratory therapists
Number of subjects: 155
Study 30920411 — intervention group
Group type: COMPARATOR
Intervention: Once daily screening led by respiratory therapists
Number of subjects: 155
Study 28282792 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 60
Study 28282792 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Number of subjects: 60
Study 28282792 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 26397992 — intervention group
Group type: EXPERIMENTAL
Intervention: Shennan definition of bronchopulmonary dysplasia
Number of subjects: 765
Study 26397992 — intervention group
Group type: EXPERIMENTAL
Intervention: National Institutes of Health Workshop definition
Number of subjects: 765
Study 26397992 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic definition after a room-air challenge
Number of subjects: 765
Study 26397992 — intervention group
Group type: COMPARATOR
Intervention: Workshop definition
Number of subjects: 765
Study 26397992 — intervention group
Group type: COMPARATOR
Intervention: Physiologic definition
Number of subjects: 765
Study 26397992 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Shennan definition
Number of subjects: 765
Study 26397992 — intervention group
Group type: COMPARATOR
Intervention: High-flow nasal cannula management
Number of subjects: 765
Study 23297184 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual counselor/clergy consultation
Number of subjects: 761
Study 23297184 — intervention group
Group type: EXPERIMENTAL
Intervention: Openness to seeking help from spiritual counselors/clergy
Number of subjects: 761
Study 23297184 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care provider openness
Number of subjects: 761
Study 23297184 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatrist openness
Number of subjects: 761
Study 23297184 — intervention group
Group type: EXPERIMENTAL
Intervention: Other mental health provider openness
Number of subjects: 761
Study 23297184 — intervention group
Group type: EXPERIMENTAL
Intervention: VA providers asking about spiritual support
Number of subjects: 761
Study 21659488 — intervention group
Group type: COMPARATOR
Intervention: Sprint exercise (30-s Wingate test) in fasting group (n = 7, C)
Number of subjects: 15
Study 21659488 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint exercise (30-s Wingate test) after glucose ingestion (n = 8, G)
Number of subjects: 15
Study 18470779 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment program based on evidence‐based treatments (EBTs) for disruptive behavior problems
Number of subjects: 117
Study 18470779 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed implementation)
Number of subjects: 117
Study 16508257 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Number of subjects: 33
Study 16508257 — intervention group
Group type: COMPARATOR
Intervention: Conventional yogurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Number of subjects: 33
Study 16508257 — intervention group
Group type: EXPERIMENTAL
Intervention: Both probiotic and conventional yogurt
Number of subjects: 33
Study 12722967 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine eyedrops
Number of subjects: 20
Study 12722967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10925331 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 42
Study 10925331 — intervention group
Group type: COMPARATOR
Intervention: Small-molecule IIb/IIIa inhibitors (eptifibatide or tirofiban)
Number of subjects: 42
Study 10925331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 8882035 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal scintigraphy using a semisolid orally ingested bolus
Number of subjects: 301
Study 8226583 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (1.5 mg/kg per day)
Number of subjects: 28
Study 8226583 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.4 mg/kg per day)
Number of subjects: 28
Study 8226583 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 28
Study 8226583 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 28
Study 8226583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3536644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure, a defined formula dietary supplement
Number of subjects: 122
Study 31498112 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective intracoronary hypothermia (SIH) during primary percutaneous coronary intervention (PPCI)
Number of subjects: 0
Study 31498112 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30088077 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine plus adrenaline
Number of subjects: 90
Study 30088077 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% tetracaine
Number of subjects: 90
Study 30088077 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine plus adrenaline
Number of subjects: 90
Study 30088077 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (NaCl)
Number of subjects: 90
Study 26635402 — intervention group
Group type: EXPERIMENTAL
Intervention: E-CPR
Number of subjects: 3756
Study 26635402 — intervention group
Group type: COMPARATOR
Intervention: C-CPR
Number of subjects: 3756
Study 24634333 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue 24 h more CPD
Number of subjects: 20
Study 24634333 — intervention group
Group type: COMPARATOR
Intervention: Discontinue CPD (control)
Number of subjects: 20
Study 22699797 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCET-PI (Primary and Secondary Control Enhancement Therapy-Physical Illness)
Number of subjects: 41
Study 22699797 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 41
Study 19940774 — intervention group
Group type: EXPERIMENTAL
Intervention: Early start of exercise training (EG) - low-intensity exercise training two times a week for 4 weeks before entering ordinary exercise training of moderate-to-high intensity (phase 2b)
Number of subjects: 39
Study 19940774 — intervention group
Group type: COMPARATOR
Intervention: Delayed start control group (CG) - entered phase 2b directly after 4 weeks of delay
Number of subjects: 39
Study 18353212 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human PEGIHN‐beta‐1a (n = 13)
Number of subjects: 21
Study 18353212 — intervention group
Group type: COMPARATOR
Intervention: PEGIHN‐beta‐1a plus ribavirin (RBV) (n = 8)
Number of subjects: 21
Study 16429182 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (no demineralizing agent)
Number of subjects: 56
Study 16429182 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (35% phosphoric acid, for 15 s)
Number of subjects: 56
Study 16429182 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (17% EDTA solution, pH 7, for 3 min)
Number of subjects: 56
Study 16429182 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (24% EDTA gel, pH 7, for 4 min)
Number of subjects: 56
Study 12360101 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg bodyweight)
Number of subjects: 534
Study 12360101 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (370 individuals)
Number of subjects: 534
Study 10353855 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine treatment
Number of subjects: 0
Study 10353855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7499620 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of care as perceived by carers through focused interviews and questionnaires
Number of subjects: 41
Study 1936109 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN) during chemotherapy
Number of subjects: 33
Study 1936109 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous oral intake only (Control)
Number of subjects: 33
Study 7287241 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg) and Tienilic acid (250 mg)
Number of subjects: 18
Study 7287241 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene (100 mg) and Tienilic acid (250 mg)
Number of subjects: 18
Study 7287241 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (10 mg) and Tienilic acid (250 mg)
Number of subjects: 18
Study 7287241 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene (200 mg) and Tienilic acid (250 mg)
Number of subjects: 18
Study 7287241 — intervention group
Group type: COMPARATOR
Intervention: Tienilic acid (250 mg)
Number of subjects: 18
Study 31261168 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of phenylephrine (P group)
Number of subjects: 51
Study 31261168 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of norepinephrine (N group)
Number of subjects: 51
Study 31261168 — intervention group
Group type: COMPARATOR
Intervention: No vasopressor (C group)
Number of subjects: 51
Study 29028556 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (45mg/day)
Number of subjects: 8
Study 29028556 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine (0, 15, and 30mg)
Number of subjects: 8
Study 29028556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 26880253 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld fan and exercise advice
Number of subjects: 49
Study 26880253 — intervention group
Group type: COMPARATOR
Intervention: Advice alone (control)
Number of subjects: 49
Study 24981955 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal treatment
Number of subjects: 60
Study 24981955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22088800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 1 million autologous cardiac stem cells (CSCs) at a mean of 113 days after surgery.
Number of subjects: 23
Study 22088800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 23
Study 19702811 — intervention group
Group type: EXPERIMENTAL
Intervention: Childbirth education class
Number of subjects: 40
Study 17476007 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg)
Number of subjects: 3889
Study 17476007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3889
Study 15008866 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% hydroquinone
Number of subjects: 50
Study 15008866 — intervention group
Group type: COMPARATOR
Intervention: 0.025% tretinoin
Number of subjects: 50
Study 11282782 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture use
Number of subjects: 76
Study 10684069 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidatum
Number of subjects: 70
Study 10684069 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 70
Study 10684069 — intervention group
Group type: COMPARATOR
Intervention: Nikethamidi
Number of subjects: 70
Study 7701971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-dependent patients
Number of subjects: 30
Study 7701971 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-dependent patients
Number of subjects: 30
Study 7701971 — intervention group
Group type: COMPARATOR
Intervention: Non-drug-dependent controls
Number of subjects: 30
Study 3109144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (250 mg four times a day for 10 days)
Number of subjects: 39
Study 3109144 — intervention group
Group type: COMPARATOR
Intervention: Penicillin (250 mg four times a day for 10 days)
Number of subjects: 39
Study 3109144 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (250 mg four times a day for 10 days)
Number of subjects: 39
Study 3109144 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous penicillin (20 million U a day for 10 days)
Number of subjects: 39
Study 3109144 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular benzathine penicillin (7.2 million U)
Number of subjects: 39
Study 3109144 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 39
Study 3109144 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous penicillin G (20 million U a day for 10 days)
Number of subjects: 39
Study 29705470 — intervention group
Group type: EXPERIMENTAL
Intervention: Black cumin oil applied by rubbing to knees 3 times a week for 1 month
Number of subjects: 60
Study 29705470 — intervention group
Group type: COMPARATOR
Intervention: Routine prescription (control group)
Number of subjects: 60
Study 26965031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 235
Study 24440931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinitapride (1 mg)
Number of subjects: 383
Study 24440931 — intervention group
Group type: COMPARATOR
Intervention: Domperidone (10 mg)
Number of subjects: 383
Study 24440931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinitapride
Number of subjects: 383
Study 24440931 — intervention group
Group type: COMPARATOR
Intervention: Domperidone
Number of subjects: 383
Study 22345157 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 20
Study 22345157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18950374 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 79
Study 18950374 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 79
Study 16011640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerana inserts
Number of subjects: 60
Study 16011640 — intervention group
Group type: EXPERIMENTAL
Intervention: SonicSys inserts
Number of subjects: 60
Study 16011640 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐quartz inserts
Number of subjects: 60
Study 16011640 — intervention group
Group type: EXPERIMENTAL
Intervention: SonicSys inserts in dentine‐bordered specimens
Number of subjects: 60
Study 16011640 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS Empress inserts (Cerana, SonicSys enamel)
Number of subjects: 60
Study 16011640 — intervention group
Group type: EXPERIMENTAL
Intervention: SonicSys inserts in deep proximal cavities
Number of subjects: 60
Study 12873927 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5%
Number of subjects: 14
Study 12873927 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.5%
Number of subjects: 14
Study 10578770 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 4 months
Number of subjects: 0
Study 10578770 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 6 months
Number of subjects: 0
Study 10578770 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacles to exclusive breastfeeding
Number of subjects: 0
Study 10578770 — intervention group
Group type: EXPERIMENTAL
Intervention: Community messages to promote EBF
Number of subjects: 0
Study 9254522 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG repeat expansion search in patients with schizophrenia and essential tremor
Number of subjects: 0
Study 9254522 — intervention group
Group type: COMPARATOR
Intervention: Control samples
Number of subjects: 0
Study 9254522 — intervention group
Group type: EXPERIMENTAL
Intervention: Locus HS0073
Number of subjects: 0
Study 9254522 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 0
Study 1895011 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐questioning strategy with self‐instructional training
Number of subjects: 60
Study 1895011 — intervention group
Group type: COMPARATOR
Intervention: Standard instruction
Number of subjects: 60
Study 1895011 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalization induction condition with informed training and self‐instructional training techniques
Number of subjects: 60
Study 6411479 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (30 mg)
Number of subjects: 9
Study 6411479 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 9
Study 31102938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite therapy
Number of subjects: 76
Study 31102938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 28379902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor (Kengreal) administered as an intravenous infusion
Number of subjects: 0
Study 28379902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor (Kengreal) as bridging therapy
Number of subjects: 0
Study 27100174 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer screening (HIP trial)
Number of subjects: 2
Study 27100174 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer screening (Age trial)
Number of subjects: 2
Study 27100174 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer screening (TCT)
Number of subjects: 2
Study 25138802 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-wave cognitive therapy (n=22)
Number of subjects: 44
Study 25138802 — intervention group
Group type: COMPARATOR
Intervention: Mentalisation-based treatment (n=22)
Number of subjects: 44
Study 23173831 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (3g daily) for 5 weeks
Number of subjects: 40
Study 23173831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19067776 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity lifestyle intervention (6 sessions/10 weeks)
Number of subjects: 152